GDF15 and glaucoma: Additionally, there is a great need for novel molecular markers of RGC health that can be used as reliable surrogate endpoints for clinical trials.[11] Although further validation is necessary to demonstrate a direct link to glaucoma progression, we propose that AH GDF15 may be a molecular marker of long-term IOP fluctuation that may be used in future therapeutic trials.